Andrew J. Last
Andrew J. Last's purchase track record
Andrew J. Last has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/17/2022 | IMDX | $17K | -55.7% | -48.5% | -3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Transaction History
| IMDX | ▼ Sell | Tax Withholding | 7,700 | $44K | 7/1/2026 | View on chart |
| IMDX | ▲ Buy | Grant | 26,943 | $0 | 6/11/2026 | View on chart |
| IMDX | ▲ Buy | Grant | 35,000 | $0 | 7/1/2025 | View on chart |
| BIO | ▲ Buy | Option Exercise | 3,000 | $898K | 9/6/2024 | View on chart |
| BIO | ▼ Sell | Open Market | 3,000 | $990K | 9/6/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 903 | $0 | 9/2/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 458 | $154K | 9/2/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,252 | $0 | 9/1/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 635 | $214K | 9/1/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 867 | $0 | 9/1/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 440 | $148K | 9/1/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 633 | $0 | 9/1/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 321 | $108K | 9/1/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,000 | $0 | 4/29/2024 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 357 | $99K | 4/29/2024 | View on chart |
| BIO | ▲ Buy | Option Exercise | 903 | $0 | 9/2/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 448 | $177K | 9/2/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 867 | $0 | 9/1/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 430 | $170K | 9/1/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 633 | $0 | 9/1/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 279 | $110K | 9/1/2023 | View on chart |
| IMDX | ▲ Buy | Grant | 20,000 | $0 | 6/23/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,000 | $0 | 4/29/2023 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 346 | $156K | 4/29/2023 | View on chart |
| BIO | ▲ Buy | Option Exercise | 902 | $0 | 9/2/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 448 | $214K | 9/2/2022 | View on chart |
| BIO | ▲ Buy | Option Exercise | 633 | $0 | 9/1/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 314 | $153K | 9/1/2022 | View on chart |
| IMDX | ▲ Buy | Open Market | 20,000 | $17K | 8/17/2022 | View on chart |
| IMDX | ▲ Buy | Grant | 10,000 | $0 | 8/15/2022 | View on chart |
| IMDX | ▲ Buy | Option Exercise | 10,000 | $0 | 6/24/2022 | View on chart |
| BIO | ▲ Buy | Option Exercise | 1,000 | $0 | 4/29/2022 | View on chart |
| BIO | ▼ Sell | Tax Withholding | 471 | $241K | 4/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
iMDx Amends Chronix Merger Deal Terms
Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.
iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.